Russia Stocks End Flat as MOEX Closes Unchanged Amid Mixed Global Signals 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025 
Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Neuralink Expands Brain Implant Trials with 12 Global Patients 
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
South Korea Exports Surge in January on AI Chip Demand, Marking Fastest Growth in 4.5 Years 
Wall Street Slides as Warsh Fed Nomination, Hot Inflation, and Precious Metals Rout Shake Markets 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
NASA Faces Major Workforce Reduction as 20% of Employees Prepare to Leave 
A South Korean research team has developed a strip-type urine test that successfully diagnoses prostate and pancreatic cancer on-site by amplifying the optical signal of the metabolome in urine.
The joint research team is from the Korea Institute of Materials Science, Pohang University of Science and Technology, and Kyung Hee University
The surface-enhanced Raman scattering sensor that they developed can amplify the optical signal of the metabolome in urine by more than 1 billion times by forming a coral reef-shaped plasmonic nanomaterial on top of porous paper material.
A light irradiation after a 10-microliter urine droplet amplified signal of cancer metabolome on the sensor’s surface without the need to go through a separate analysis process,.
The application of an artificial intelligence-based analytical method for the spectrum signal generated through the irradiation of light into the urine can identify people with prostate cancer and pancreatic cancer with an accuracy of up to 99 percent.
